Get the Stockscreener App
39.16
0.33%
0.1496
Indivior Pharmaceuticals Inc stock is traded at $39.16, with a volume of 937.04K.
It is up +0.33% in the last 24 hours and down -3.45% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$39.01
Open:
$38.95
24h Volume:
937.04K
Relative Volume:
0.48
Market Cap:
$4.62B
Revenue:
$1.29B
Net Income/Loss:
$251.00M
P/E Ratio:
19.83
EPS:
1.9744
Net Cash Flow:
$-193.86M
1W Performance:
+1.74%
1M Performance:
-3.45%
6M Performance:
+12.63%
1Y Performance:
+66.84%
1-Day Range:
$38.68
$39.59
1-Week Range:
$37.82
$39.59
52-Week Range:
$22.22
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
39.16 | 4.60B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
17.36 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.45 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.585 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.60 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
505.62 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Indivior Q2 2026 Earnings Call: Complete Transcript - Benzinga
Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView
Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Layoff Tracker: MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles - BioSpace
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
Indivior Plc (INDV) News, Articles, Events & Latest Updates - Stocktwits
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - uk.finance.yahoo.com
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Exploring a 27% Potential Upside Amid Strong Revenue Growth - directorstalkinterviews.com
Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV - MarketBeat
Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - tradingview.com
Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz
Indivior Pharmaceuticals Inc (INDV) Shares Surge 6.1% -- What GF Score of 75 Tells Investors - GuruFocus
Indivior Pharmaceuticals (INDV) CAO purchases 1,500 common shares - Stock Titan
Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0
Earnings call transcript: Supernus jumps on Indivior merger in Q2 2026 - Investing.com Nigeria
Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - Moomoo
Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative
Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance
Indivior Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance
Raleigh drug factory part of $2B merger - The Business Journals
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential - DirectorsTalk Interviews
Supernus, Indivior merge to strengthen neuroscience drug portfolio - 1470 & 100.3 WMBD
Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals - Stock Titan
Supernus Pharmaceuticals (SUPN) outlines investor and employee outreach on Indivior merger of equals - Stock Titan
Indivior Pharmaceuticals, Inc. 2026: Revenue $343M, EPS $0.98— 10-Q Summary - TradingView
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News
Indivior Falls as Investors Reposition Ahead of Second-Quarter Results - Quiver Quantitative
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue - Benzinga
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook - Yahoo Finance
Supernus Pharmaceuticals (SUPN) details Indivior merger call and planned S-4 proxy filings - Stock Titan
Indivior Pharmaceuticals Inc. R (E7P.MU) Q2 FY2026 & Merger earnings call transcript - Yahoo Finance
CNS-focused Supernus and Indivior agree merger terms - pharmaphorum
Supernus and Indivior agree to merge in all-stock deal - Investing.com
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates - finance.yahoo.com
Weekly Recap: All-stock merger with Supernus and 2026 SUBLOCADE guidance - TradingView
Weekly Recap: Indivior merger, 1.5401 exchange and Q2 revenue, guide up - TradingView
Supernus Pharmaceuticals (SUPN) agrees merger-of-equals with Indivior and $1B special dividend - Stock Titan
Indivior (INDV) Q2 2026: EPS Beats by 25%, SUBLOCADE Sets Record - 24/7 Wall St.
Supernus and Indivior agree to merge in all-stock deal By Investing.com - Investing.com Nigeria
Indivior Pharmaceuticals Q2 Non-GAAP Earnings, Revenue Rise; 2026 Sales Outlook Upgraded - Yahoo Finance
Indivior Reports Record Q2 2026 Revenue, SUBLOCADE Sales and Profitability; Raises Full-Year Guidance Amid Supernus Merger Announcement - Quiver Quantitative
Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance - TradingView
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Indivior Pharmaceuticals Inc Stock (INDV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Heidbreder Christian | Chief Scientific Officer |
Jul 10 '26 |
Sale |
41.14 |
18,586 |
764,628 |
209,337 |
1.76%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):